德谷胰岛素及其复方制剂的临床研究进展

Progress in clinical research of insulin degludec and its compound preparations

德谷胰岛素是新一代超长效基础胰岛素类似物,用于1型和2型糖尿病的治疗。德谷胰岛素可以形成多六聚体结构而缓慢释放进入血液循环系统,半衰期长,注射后具有平稳的药代动力学曲线。多项临床试验已经证实了德谷胰岛素及其复方制剂DegludecPlus、IDegLira具备良好的安全性和有效性,可持久、平稳、长期降糖,且低血糖风险小,并能减少胰岛素注射次数,为糖尿病病人的胰岛素治疗提供了一种新选择。

Insulin degludec is a new generation of ultra-long-acting insulin analogues for the treatment of type 1and type 2diabetes.Insulin degludec can form a multi-hexamer structure to release the monomers slowly when entering the blood circulation,which results in a long half-life after injection and a smooth pharmacokinetic curve.The safety and efficacy of degludec and its compound preparations DegludecPlus,IDegLira have been confirmed through several major clinical trials.These drugs can reduce the HbA1 clevel durably and stably,and have a relatively small risk of hypoglycemia.They can also reduce the frequency of insulin injections,which will be a new choice for diabetes insulin-treated patients.